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Most studies on TCF7L2 SNP variants in the patho-
genesis of type 2 diabetes (T2D) focus on a role of
the encoded transcription factor TCF4 in b cells.
Here, a mouse genetics approach shows that
removal of TCF4 from b cells does not affect their
function, whereas manipulating TCF4 levels in the
liver has major effects on metabolism. In Tcf7l2/
mice, the immediate postnatal surge in liver metabo-
lism does not occur. Consequently, pups die due to
hypoglycemia. By combining chromatin immunopre-
cipitation with gene expression profiling, we identify
a TCF4-controlled metabolic gene program that
is acutely activated in the postnatal liver. In con-
cordance, adult liver-specific Tcf7l2 knockout
mice show reduced hepatic glucose production
during fasting and display improved glucose homeo-
stasis when maintained on high-fat diet. Further-
more, liver-specific TCF4 overexpression increases
hepatic glucose production. These observations
imply that TCF4 directly activates metabolic genes
and that inhibition of Wnt signaling may be beneficial
in metabolic disease.
INTRODUCTION
Wnt signaling controls virtually every aspect of embryonic
development and mediates homeostatic self-renewal in adult
tissues (Clevers and Nusse, 2012). When Wnt ligands bind to
the Frizzled-Lrp5/6 receptor complex, it results in the stabiliza-
tion and subsequent nuclear translocation of b-catenin. In the
nucleus, stabilized b-catenin binds to TCF transcription factors
to regulate the transcription of Wnt target genes.CEpidemiological evidence suggests that Wnt signaling may
also play a role in metabolic disorders. Grant and colleagues
identified a strong association between T2D risk and intronic
SNPs in TCF7L2 (Grant et al., 2006). Many follow-up studies
have confirmed this discovery (Cauchi et al., 2007; Elbein
et al., 2007; Florez et al., 2006). Individuals with variants of
TCF7L2 associated with increased risk for T2D show impaired
insulin secretion (Florez et al., 2006; Saxena et al., 2006) and
present an increased hepatic glucose production in fasting
(Lyssenko et al., 2007).
Tcf7l2 mutant mice, which die in the immediate postnatal
period, do not maintain stem cells in their intestinal crypts (Kor-
inek et al., 1998). Moreover, the encoded TCF4 transcription
factor activates the oncogenic program that is aberrantly
activated in APC mutant colon cancer cells (Korinek et al.,
1997; van deWetering et al., 2002). In a recent study by Nobrega
and colleagues, copy numbers of Tcf7l2 were varied by trans-
genesis. Increased copy numbers of Tcf7l2 rendered mice
glucose intolerant, whereas decreasing gene copy numbers re-
sulted in enhanced glucose tolerance (Savic et al., 2011). These
observations imply that the human risk alleles of TCF7L2 repre-
sent gain-of-function alleles for an as-yet-undefined role of TCF4
in metabolic control. Here, we address the tissue of action and
the molecular mechanism of metabolic control by TCF4 by using
mouse models allowing constitutive knockout, tissue-specific
knockout, and transient overexpression of Tcf7l2.
RESULTS
Deletion of Tcf7l2 in Insulin-Producing Cells Does
Not Cause b Cell Dysfunction
The association of TCF7L2/TCF4 with T2D prompted us to
compare Tcf7l2 heterozygous with wild-type (WT) mice, ad-
dressing the possible role of TCF4 in metabolic regulation. We
observed a difference in their body weight, with Tcf7l2+/ mice
displaying more than 20% lower body weight compared to WTell 151, 1595–1607, December 21, 2012 ª2012 Elsevier Inc. 1595
littermates. TCF4 heterozygosity reduces glucose, insulin, fatty
acid, triglyceride, and cholesterol levels in adult mice (data not
shown). Tcf7l2+/ mice also have increased insulin sensitivity,
improved glucose tolerance, and reduced capacity to produce
glucose after pyruvate injection, even when they are fed with
a 45% high-fat (HF) diet (data not shown), confirming previous
observations (Savic et al., 2011).
Human carriers of the risk variants for TCF7L2 reportedly
display impaired insulin secretion (Florez et al., 2006; Saxena
et al., 2006). We generated a Tcf7l2 allele with loxP sites flanking
exon 10 (van Es et al., 2012), which encodes the DNA-binding
HMG box (Korinek et al., 1998). Tcf7l2loxP/+ mice were bred
with the tamoxifen-inducible pancreatic b-cell-specific Cre
recombinase strain RIP-Cre-ERT2 (Dor et al., 2004). Because
we did not observe any difference between the three controls
(Tcf7l2 loxp/loxp, RIP-Cre-ERT2, and WT) in body weight, blood
glucose and plasma insulin levels, glucose tolerance test,
and insulin secretion in vivo in the initial experiments (Figures
S1A–S1E available online), we decided to use in the follow-up
experiments Tcf7l2loxp/loxp; RIP-Cre-ERT2 (bTCF4KO) and
Tcf7l2loxp/loxp as control mice. Both groups of mice were injected
with tamoxifen at weaning and were analyzed at the age of 2 to
3 months.
PCR and real-time RT-PCR were performed to quantify
recombination of the Tcf7l2 locus and depletion of Tcf7l2
messenger RNA (mRNA) in b cells. As shown in Figure S2A,
a single 1,132 bp band was observed in islets from controls. In
contrast, by using DNA prepared from islets from bTCF4KO
mice, themajor product was 611 bp, indicating exon 10 deletion.
Tcf7l2 mRNA was strongly reduced in isolated islets from
bTCF4KO mice (Figure 1K). The remaining Tcf7l2 mRNA can
be accounted for by the fact that b cells only make up 80%–
85% of islets.
We compared a set of metabolic parameters between adult
bTCF4KO mice and control littermates on normal chow (NC)
diet (Figure 1). Surprisingly, bTCF4KO mice were able to main-
tain euglycemia as compared to control littermates in the fed
and the fasted state (Figure 1A). We did not detect any difference
either in plasma insulin levels (Figure 1B) or in the ratio insulin/
glucose (Figure 1C) in both states. When mice were exposed
to a 45% HF diet (Figure S2), we observed no differences in
body weight, gain of body weight, food intake, blood glucose,
and plasma insulin levels between bTCF4KO and control mice
(Figures S2B–S2G). To characterize physiological responses to
glucose load, bTCF4KO and control mice on either NC (Fig-
ure 1D) or HF (Figure S2H) diet were subjected to an intraperito-
neal (i.p.) glucose tolerance test after a 16 hr fast. This revealed
no difference in glucose tolerance on either NC (Figure 1D) or
HF (Figure S2H) diet. When mice on either NC (Figure 1E) or
HF (Figure S2I) diet were injected with insulin to test their insulin
tolerance, we did not observe any difference between both
genotypes.
Then, insulin release was measured in response to glucose
stimulation in vivo. The increase in plasma insulin levels 15 min
after i.p. glucose injection did not differ between bTCF4KO and
control mice on either NC (Figure 1F) or HF diet (Figure S2J).
We also isolated pancreatic islets from bTCF4KO and control
mice on either NC (Figure 1G) or HF (Figure S2K) diet for 8 weeks1596 Cell 151, 1595–1607, December 21, 2012 ª2012 Elsevier Inc.and tested insulin secretion in vitro. Under both feeding condi-
tions, insulin release was equal at low (1.6 mM) and high
(16.7 mM) glucose concentrations between bTCF4KO and
control mice. Total insulin content did not differ between islets
isolated from bTCF4KO and control mice in both feeding condi-
tions (Figures 1H and S2L). Accordingly, histological analysis
revealed no differences in pancreatic islets and in b cell mass
(Figure 1I). Ki67 staining also revealed no effect of TCF4 deletion
on b cell proliferation (Figure 1J).
We also measured the mRNA levels of genes relevant for
maintaining b cell function in isolated pancreatic islets. As
expected, Tcf7l2 mRNA levels were dramatically reduced in
the pancreatic islets of bTCF4KO mice (p < 0.01) (Figures 1K
and S2M). Levels of Ins1 and Ins2 and Gcg and Iapp were
indistinguishable from that of controlmice both onNC (Figure 1K)
and HF (Figure S2M) diets. Neither the mRNA levels for enzymes
involved in glucose metabolism (Gck, Pklr, and G6pc2) nor
receptors for insulin release and glucose sensing (Insr, Gipr,
Glp1r, and Slc2a2) were affected by depletion of TCF4. More-
over, the expression of b cell transcription factors (Pdx1,
NeuroD1, Nkx2.2, Nkx6.1, Isl1, and FoxO1) was not affected in
isolated pancreatic islets of bTCF4KO mice (both on NC [Fig-
ure 1K] and HF [Figure S2M] diets). Of interest, Axin2 and Sp5,
two generic Wnt target genes (Lustig et al., 2002; Weidinger
et al., 2005), showed no change both on NC (Figure 1K) and
HF (Figure S2M) diets, implying that TCF4-dependent Wnt
signaling is not operative in pancreatic b cells.
Tcf7l2/ Newborns Die Because of Hypoglycemia
The lack of a metabolic phenotype of the bTCF4KOmice promp-
ted us to reassess the Tcf7l2/ model. Tcf7l2/ newborns
appeared developmentally normal at birth yet displayed
a reduced body weight (Figure 2A). They became lethargic within
hours after birth, presumably because of lack of energy to
compete for nourishment, and typically died after 8 hr (Figure 2D).
Just after birth, glucose levels appeared indistinguishable
between Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ newborns (data not
shown). However, glucose levels were significantly lower at
3 hr postpartum (hpp) in the Tcf7l2/ newborns (Figure 2B)
than in littermates. The hypoglycemia was caused neither by
glycosuria (data not shown) nor by excessive insulin secretion,
as plasma insulin levels were also significantly lower in Tcf7l2/
mice than in their Tcf7l2+/+ and Tcf7l2+/ littermates (Figure 2C).
The Tcf7l2/ newborns could be rescued for up to 32 hr by
subcutaneous injections of 50 ml of 10% glucose at birth and
every 6 hr thereafter (p < 0.001) (Figure 2D).
Hepatic Glucose Metabolism Is Affected in Tcf7l2/
Newborns
To circumvent confounding consequences of feeding, we
removed all pups from the mothers directly after birth and
analyzed metabolic parameters 5 hr later (5 hpp). To ensure
survival of the newborns, all mice were given a single subcuta-
neous glucose injection at birth. Blood glucose levels and
plasma insulin levels were indistinguishable between 5 hpp
Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ (Figures 3A and 3B)
newborns. This was in line with the previous results obtained in
adult mice, where the absence of TCF4 did not prevent b cells
Figure 1. b-Cell-Specific Deletion of Tcf7l2
Does Not Affect Islet Architecture and
Pancreatic b Cell Function In Vivo and
In Vitro
(A–C) (A) Blood glucose, (B) plasma insulin, and (C)
ratio insulin versus glucose levels in fed state
(Fed) and after a 16 hr fasting (Fasted) in control
(Tcf7l2 loxp/loxp) and bTCF4KO (Tcf7l2 loxp/loxp ;RIP-
Cre-ERT2) littermates at the age of 12 weeks.
(D and E) (D) GTT and (E) ITT were performed in
bTCF4KO and control mice after 16 hr and 4 hr
fasting, respectively.
(F) After 16 hr of fasting, plasma insulin levels were
measured at time 0 and 15 min after glucose
injection to test insulin secretion in vivo in
bTCF4KO and control mice.
(G) Insulin release did not differ between control
and bTCF4KO isolated pancreatic islets at 1.6 mM
and 16.7 mM glucose.
(H) Total insulin content also did not differ between
control and bTCF4KO pancreatic islets.
(I) Pancreatic islets from control and bTCF4KO
adult mice. Sections were stained with anti-insulin
(red) and anti-glucagon (green) antibodies. b cell
mass did not differ between control and bTCF4KO
mice, n = 4 per genotype.
(J) Pancreatic islets from control and bTCF4KO
adult mice stained with anti-KI67 (green) and anti-
insulin (red) antibodies, n = 4 per genotype.
(K) qRT-PCR to measure relative Tcf7l2 and the
Wnt target genes as well as the mRNA levels of
relevant genes for b cell function in isolated
pancreatic islets from control and bTCF4KO mice,
n = 8 per genotype.
All data are represented as mean ±SEM; n =
12–15 per genotype; **p < 0.01. See also Figures
S1 and S2.from secreting insulin after glucose stimulation. Indeed, embry-
onic development of the endocrine pancreas, b cell proliferation,
and expression of relevant b cell genes appeared normal in
Tcf7l2/ newborns (Figures S3A–S3C).
The liver occupies a central position in metabolic adaptation
after birth, particularly in glucose homeostasis. Initially, hepatic
glucose is released from glycogen stores. After several hours
of fasting, gluconeogenesis, the production of glucose from
lactate and pyruvate, becomes the major source of glucose
(Gustafsson, 2009; Pilkis and Granner, 1992). We analyzedCell 151, 1595–1607, Deperiodic acid Schiff (PAS) staining for
glycogen at late stages of embryonic
development and after birth. At E18.5,
Tcf7l2/ andWT livers had accumulated
similar levels of glycogen (Figure 3C,
top), implying that glycogen metabolism
is not affected by TCF4 during embryonic
development. In contrast, histological
sections and measurement of glycogen
content of liver samples from 5 hpp
Tcf7l2/mice revealed strongly reduced
glycogen storage (p < 0.01) (Figure 3C,
bottom, and Figure 3D).mRNA expression levels of enzymes important for glycogen
metabolism (Gys2, Pygl, and Gyg) and gluconeogenesis (Pck1,
G6pc, and Fbp1) were analyzed by qRT-PCR in embryonic and
5 hpp Tcf7l2/ and WT livers. Expression of Gys2, the enzyme
that catalyzes the rate-limiting step in the synthesis of glycogen
(Ferrer et al., 2003), was significantly downregulated in 5 hpp
Tcf7l2/ livers (p < 0.05) (Figure 3E). Consistent with an activa-
tion of the gluconeogenic pathway at birth, Pck1, G6pc, and
Fbp1 mRNA levels were upregulated in the WT newborn livers
compared with the embryonic livers. The induction of Pck1 andcember 21, 2012 ª2012 Elsevier Inc. 1597
Figure 2. Tcf7l2/ Newborns Succumb to Acute Hypoglycemia
(A–C) (A) Body weight, (B) blood glucose, and (C) plasma insulin levels in 3 hpp Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ newborns.
(D) After subcutaneous administration of glucose at birth and every 6 hr thereafter, the life span of the Tcf7l2/ newborns can be extended significantly
(p < 0.0001) compared with nontreated Tcf7l2/ newborns.
Data are represented as mean ±SEM. *p < 0.05, **p < 0.01, and ***p < 0.001; n = 12–15 per genotype. See also Figure S3.G6pc was significantly reduced in the 5 hpp Tcf7l2/ newborn
livers when compared with WT littermates (p < 0.05) (Figure 3F).
Tcf7l2/ Newborns Have Disrupted Hepatic Lipid
Metabolism
After birth, triglyceride synthesis, fatty acid oxidation, and ketone
body synthesis are also enhanced in the early postnatal liver
(Ferre´ et al., 1986). To determine the effect of TCF4 depletion
on lipid metabolism, concentrations of free fatty acids (FFA),
triglycerides, and ketone bodies were measured in the serum
of 5 hpp Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ newborns, previously
removed from their mothers and injected with glucose at birth.
Serum FFA, triglycerides, and ketone bodies levels were signifi-
cantly reduced in 5 hpp Tcf7l2/ newborns (p < 0.01 and
p < 0.05) (Figures 4A–4C). We then assessed hepatic lipid distri-
bution with oil red O staining. Embryonic livers from WT and
Tcf7l2/mice were indistinguishable, presenting few small lipid
droplets (Figure 4D, top). However, 5 hpp WT livers showed
a strong increase in lipid, which was not observed in Tcf7l2/
livers (Figure 4D, bottom). In concordance, triglyceride content
was significantly reduced in 5 hpp Tcf7l2/ livers when
compared with Tcf7l2+/+ and Tcf7l2+/ (p < 0.01) (Figure 4E).1598 Cell 151, 1595–1607, December 21, 2012 ª2012 Elsevier Inc.Changes in serum and hepatic lipid levels were possibly
secondary to changes in gene expression of relevant enzymes
in hepatic lipid metabolism. Indeed, the upregulation of genes
involved in different aspects of fatty acid biosynthesis observed
in 5 hhp WT livers was again abolished in 5 hpp Tcf7l2/ livers.
This included Acadl and Ehhadh (p < 0.05 and p < 0.01) (Fig-
ure 4F). Similarly, decreases were detected in the expression
of several enzymes involved in b-oxidation, such as Acaa1a
and Acot4 (p < 0.05 and p < 0.01) (Figure 4G), and genes implied
in ketogenesis and cholesterol metabolism, such as Fgf21,
Akr1c6, and Cyp7a1 (p < 0.05) (Figure 4H).
Strong Upregulation of Wnt, Liver-Zonated, and
Metabolic Genes in Postnatal Livers in a TCF4-
Dependent Manner
The failed postnatal upregulation of multiple metabolic genes
prompted us to address the possibility that these genes are
regulated by the Wnt pathway effector TCF4. To identify the
hepatic transcriptional signature dependent on TCF4, we per-
formed comparative gene expression profiling on livers of 5
hpp newborns. 960 genes were differentially expressed between
Tcf7l2/ and Tcf7l2+/+ livers (as arbitrarily defined by >2-fold
Figure 3. Tcf7l2 Deficiency Results in Impaired Carbohydrate
Metabolism in the Newborn Liver
(A and B) (A) Blood glucose and (B) plasma insulin levels were measured in
Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ 5 hpp newborns.
(C) PAS staining for glycogen (magenta) in livers from day 18.5 Tcf7l2+/+ and
Tcf7l2/ fetuses (top) and 5 hpp Tcf7l2+/+ and Tcf7l2/ newborns (bottom).
Scale bar, 100 mm.
(D) Glycogen levels were measured in Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ livers
from 5 hpp newborns.
(E and F) (E) qPCR to measure relative mRNA levels of genes involved in
glycogenmetabolism and (F) gluconeogenesis, from either embryonic or 5 hpp
Tcf7l2+/+ and Tcf7l2/ livers. All qRT-PCR results were normalized to
housekeeping mRNA levels and were expressed relative to Tcf7l2+/+ embry-
onic samples.
All data are represented as mean ±SEM; n = 6–12 per genotype; *p < 0.05 and
**p < 0.01.
Figure 4. Tcf7l2 Deficiency Results in Impaired Lipid Metabolism in
the Newborn Liver
(A–C) (A) Serum fatty acids, (B) triglycerides, and (C) ketone bodies levels were
measured in Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ 5 hpp newborns.
(D) Oil red O staining for lipid droplets (red) in livers from day 18.5 Tcf7l2+/+ and
Tcf7l2/ fetuses (top) and 5 hpp Tcf7l2+/+ and Tcf7l2/ newborns (bottom).
Scale bar, 100 mm.
(E) Triglyceride levels were measured in Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/
livers from 5 hpp newborns.
(F–H) (F) qPCR to measure relative mRNA levels of genes involved in fatty acid
metabolism, (G) b-oxidation, and (H) ketogenesis and cholesterol metabolism
from either embryonic or 5 hpp Tcf7l2+/+ and Tcf7l2/ livers. All qRT-PCR
results were normalized to housekeeping mRNA levels and are expressed
relative to Tcf7l2+/+ embryonic samples.
All data are represented as mean ±SEM; n = 6–12 per genotype; *p < 0.05 and
**p < 0.01.expression difference; p < 0.05) (Table S1 and Figure 5A). In the
list of genes with lower expression in the mutant mice, we found
metabolic genes such as Aqp9, Slc17a2, and Akr1c6. We also
noted differential expression levels of the generic Wnt target
genes Axin2 and Sp5 between Tcf7l2/ and Tcf7l2+/+ neonatal
livers (Figure 5D). A previous report has implicated Wnt signaling
in the zonation of genes in adult liver and has identified several
liver-specific Wnt/b-catenin target genes such as Glul andCell 151, 1595–1607, December 21, 2012 ª2012 Elsevier Inc. 1599
Figure 5. Wnt-Dependent, Liver-Zonated, and Metabolic Genes Are Upregulated in Liver after Birth in a TCF4-Dependent Manner
(A) Heatmap showing genes downregulated more than 2-fold with p < 0.05 after mean centering in Tcf7l2/ versus Tcf7l2+/+ newborn livers. Red, upregulated;
green, downregulated; black, no change; gray, missing data. Representatives of TCF4 metabolic target genes are listed on the right.
(B–F) (B) qRT-PCR tomeasure relative Tcf7l2, (C) Wnt genes, (D)Wnt target genes, (E) liver-zonated genes, and (F) metabolic genemRNA levels in embryonic and
5 hpp liver samples from Tcf7l2+/+ and Tcf7l2/ mice, respectively. All qRT-PCR results were normalized to housekeeping mRNA levels and are expressed
relative to Tcf7l2+/+ embryonic samples.
Data are represented as mean ±SEM; n = 8 per genotype; *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S4 and Table S1.Rnase4 (Benhamouche et al., 2006). These Wnt-driven zonation
genes were also differentially expressed between Tcf7l2/ and
Tcf7l2+/+ neonatal livers (Figure 5E). These observations implied
that Wnt signals, mediated through TCF4, are operative in the
early postnatal liver.
Given that the metabolic phenotypes were observed in
Tcf7l2/ postnatal livers, but not during embryonic develop-
ment, we hypothesized that TCF4 transcriptional target gene
expression may follow the same pattern. As expected, there
were no significant differences in the mRNA levels of the two
prototypic Wnt-responsive genes Axin2 and Sp5 in Tcf7l2/
embryonic liverswhen comparedwithWT littermates (Figure 5D).
When we compared mRNA levels between late embryonic and 5
hppWT livers, we noted a dramatic upregulation of these generic
Wnt target genes (Figure 5D), implying that the Wnt pathway is
acutely activated directly after birth. This induction did not occur
in the Tcf7l2/ newborn livers (p < 0.05) (Figure 5D). Indeed, we
observed an increase in the expression levels of several Wnt
genes in postnatal livers when compared with their embryonic
levels (p < 0.05 and p < 0.01) (Figure 5C). There was also a signif-
icant upregulation after birth of the liver-zonated Wnt-target1600 Cell 151, 1595–1607, December 21, 2012 ª2012 Elsevier Inc.genes Glul and Rnase4, again in a TCF4-dependent manner
(p < 0.05) (Figure 5E). Of note, Tcf7l2 mRNA levels were not
increased after birth (Figure 5B).
As noted above, the microarray list of genes that were low in
Tcf7l2/ newborn livers compared to controls contained
multiple genes relevant to the metabolic functions of the liver,
such as Aqp9, an essential glycerol transporter (Rojek et al.,
2007); Cyp2e1, a monooxygenase member of the cytochrome
P450 superfamily that catalyzes steps in the synthesis of choles-
terol, steroids, and other lipids (Lieber, 1997); and Hmgcs2, the
rate-limiting enzyme in the ketogenesis pathway, providing
lipid-derived energy in neonates and in times of carbohydrate
deprivation (Dashti and Ontko, 1979) (Table S1). In line with the
previous observations inWnt and liver-zonated genes,metabolic
genes such as Cyp2e1, Cyp2c39, Hmgcs2, Aqp9, Slc17a2, and
Slc27a2 were significantly upregulated postnatally in WT livers,
but such upregulation did not occur in the Tcf7l2/ postnatal
livers (p < 0.05 and p < 0.01) (Figure 5F). These differences
were also observed between 5 hpp Tcf7l2+/+ and Tcf7l2/ livers
at the protein level by immunostaining and western blot analysis
for AQP9, CYP2E1, and SLC27A2 (Figures S4A and S4B).
TCF4 Directly Regulates the Expression of Key Genes
Involved in Metabolic Pathways
The transcriptional signature of Tcf7l2/ postnatal livers sug-
gested that TCF4 might activate the expression of the pertinent
metabolic genes directly. We performed chromatin immunopre-
cipitation sequencing (ChIP-seq) experiments on chromatin
prepared from livers of 1-week-old WT mice. 5,092 potential
TCF4 binding sites were identified (at a 10% false discovery
rate) (Figures 6A, 6B, S5A, and S5B and Table S2). The most
common sequence motif in the TCF4-binding regions closely
resembled the cognate TCF-binding motif (Figure 6C and Table
S3) (Hatzis et al., 2008; van deWetering et al., 1997). GSEA anal-
ysis showed a significant enrichment of genes with TCF4 binding
sites within 5 kb from their transcription start sites (TSSs) among
the genes with decreased expression in newborn Tcf7l2/ livers
(Figure 6D). Thus, we identified TCF4 peaks in the TSSs of
general Wnt target genes such as Axin2 and Sp5 (Hatzis et al.,
2008), which coincidedwith similar peaks in intestinal crypt chro-
matin (Figures 6A and S5A). We also identified TCF4 peaks in the
vicinity of the TSSs of the liver-zonated genes Glul and Rnase4
(Figures 6A and S5A). These results were confirmed by qPCR
(p < 0.05, p < 0.01, and p < 0.001) (Figures 6E and S5C).
We then performed Gene Ontology (GO) analysis (Eden et al.,
2009) on a set of genes defined as being >1.5-fold downregu-
lated in the Tcf7l2/ postnatal livers and containing at least
one TCF4-bound region within 5 kb from the TSS. Among the
functional categories significantly enriched in this gene set (p <
0.001), the overwhelming majority was involved in metabolic
processes, including carbohydrate, steroid, ketone, and lipid
metabolism (Table S4). Among these key liver metabolic genes
identified as novel TCF4 target genes, we noted, among others,
Aqp9, Acadl, Akr1c6, Cyp2e1, Cyp2c39, Slc25a21, and
Hmgcs2a (Figures 6B, 6E, S5B, and S5C). As a further validation
to the ChIP-seq data, we cloned the Sp5, Rnase4, Cyp2e1, and
Akr1c6 promoters and the putativeAqp9 enhancer in a luciferase
reporter plasmid. Transient transfections were performed in
HepG2 cells, a human hepatocarcinoma cell line in which Wnt
signaling is constitutively active due to a b-catenin mutation
(de La Coste et al., 1998). Figure 6F shows spontaneous activity
of the b-catenin/TCF reporter plasmid TOPflash (Korinek et al.,
1997) and of all putative regulatory sequences due to the activa-
tion of Wnt signaling in this cell line. As a negative control, we
used the mutant FOP reporter plasmid (Figure 6F). In order to
demonstrate that the measured transcriptional activity was
dependent on TCF4, all constructs were cotransfected with
a TCF4 dominant-negative (DNTCF4) expression plasmid (Hatzis
et al., 2008; van deWetering et al., 2002). As expected, luciferase
activity was significantly reduced upon DNTCF4 overexpression
(and consequent reduction ofWT TCF4 activity) (p < 0.05 and p <
0.01) (Figure 6G), corroborating that this set of metabolic genes
is regulated directly by TCF4.
In Adult Liver, TCF4 Is Involved in the Transcriptional
Activation of Genes Implicated in the Response to
Fasting
As TCF4 is a critical regulator of neonatal hepatic metabolism
in vivo and as a loss of TCF4 leads to lethal hypoglycemia in
newborn mice, we investigated whether depletion of TCF4 inCadult liver would alter glucose homeostasis. For the generation
of liver-specific TCF4 knockout mice (LTCF4KO), we followed
the same strategy that we have described previously for gener-
ating bTCF4KO mice but instead bred Tcf7l2loxP mice with the
tamoxifen-inducible liver-specific Cre recombinase strain SA-
Cre-ERT2 (Schuler et al., 2004). In all experiments, Tcf7l2loxp/loxp;
SA-Cre-ERT2 (LTCF4KO) and Tcf7l2loxp/loxp control mice were
injected with tamoxifen after weaning and were analyzed at the
age of 2 to 3 months.
To determine the efficiency of recombination of the Tcf7l2
gene in the liver, genomic PCR and real-time PCR were per-
formed. As shown in Figure S6A, recombination took place
specifically in DNA samples from LTCF4KO livers. In concor-
dance, expression of Tcf7l2 mRNA was strongly reduced in the
livers from LTCF4KO mice when compared with control mice
(Figure S6B). LTCF4KO mice did not differ in body weight from
their control littermates on NC diet (Figure S6D). However, we
observed significantly reduced glucose levels in fasting
LTCF4KO mice when compared to control mice (Figure S6G).
This reduced glucose level was not caused by hyperinsulinemia
(Figures S6H and S6I). Indeed, glucose-stimulated insulin secre-
tion did not differ between LTCF4KO and control mice onNC diet
(Figure S6M).
Based on the fact that newborn Tcf7l2/ and adult LTCF4KO
showed decreased blood glucose levels upon fasting, we as-
sessed the hepatic response to long-term fasting in LTCF4KO
mice. Blood glucose measurements were taken from LTCF4KO
mice along with control littermates at regular intervals during
a 24 hr fasting period. We found significantly reduced blood
glucose levels between LTCF4KO and control mice from 9 hr
onward during the 24 hr fasting period (p < 0.05) (Figure 7A).
No differences in blood glucose levels were observed in mice
fed ad libitum with NC diet (Figures 7A and S6G). To explore
the possible mechanism underlying the reduced glucose levels
observed in LTCF4KO mice during long fasting periods, we
compared microarray data from livers of control mice in fed
and 24-hr-fasted states in order to identify the genes upregu-
lated in response to fasting. 623 genes were differentially ex-
pressed between fed and 24-hr-fasted control livers (as defined
by being >2-fold upregulated; p < 0.05) (Table S5 and Figure 7B).
The induction of this set of genes upon fasting was generally
much less prominent in LTCF4KO samples (Table S5 and Fig-
ure 7B). GSEA analysis showed a significant enrichment of
genes with at least one TCF4 peak within 5 kb from the TSS
among the genes differentially expressed between LTCF4KO
versus control livers fasted during 24 hr (24-hr-fasted p < 0.001
versus fed p < 0.789) (Figure 7C and data not shown). Further-
more, GSEA analysis showed a significant enrichment of meta-
bolic pathways, such as glycolysis and gluconeogenesis,
biosynthesis of steroids, and fatty acid metabolism in the set of
genes that were lower in 24-hr-fasted LTCF4KO livers when
compared with 24-hr-fasted control livers (Table S6). In contrast,
GSEA did not find any metabolic category significantly enriched
when fed LTCF4KO livers were compared with fed control livers
(data not shown).
Between fed and 24-hr-fasted control livers, we noted an up-
regulation of the generic Wnt targets genes Axin2 and Sp5 (Fig-
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Figure 6. Enrichment of TCF4 Binding in the Vicinity of Metabolic Genes Expressed in Newborn Liver
(A and B) Schematic representation of (A) Axin2 and Rnase4 and (B) G6pc, Pck1, Aqp9, and Acadl loci, indicating the location of ChIP-seq TCF4 peaks in mouse
intestinal crypt and liver chromatin. Location of the PCR products detected by qPCR to confirm the ChIP-seq results are indicated in red.
(C) Sequence logos illustrating the TCF/LEF in silico motif and the most enriched motif in the TCF4 ChIP-seq peaks in chromatin from liver.
(legend continued on next page)
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fasting. This induction did not occur in the LTCF4KO livers (Fig-
ure S7H). The liver-zonated Wnt/b-catenin target genesGlul and
Rnase4 were also significantly upregulated during fasting in
a TCF4-dependent fashion (Figure S7H). This implied that
TCF4 is involved in aWnt-driven transcriptional response to fast-
ing. In agreement, fasting increased Wnt2b, Wnt4, and Wnt9b
expression in control liver (Figure S6C). We also examined the
hepatic mRNA levels of known genes involved in fasting such
as Aldh3a2, St3gal5 (Sanderson et al., 2009), and Slc1a2 (Table
S5 and Figure 7D). Expression was upregulated after 24 hr of
fasting, and their induction was abolished by TCF4 ablation
(p < 0.01) (Figure 7D). Additionally, the fasting-mediated mRNA
induction of one of the key gluconeogenic enzymes, G6pc,
was significantly reduced in LTCF4KO liver samples (p < 0.05)
(Figure 7D). Importantly, analysis of the ChIP-seq data and
qPCR demonstrated the presence of TCF4 peaks in near meta-
bolic genes involved in the response to fasting such as G6pc,
Aldh3a2, and Slc1a2 (Figures 6B, 6E, S5B, and S5C). Of note,
TCF4 was not significantly enriched in the vicinity of Pck1,
Fbp1, and St3gal5 genes (Figures 6B, 6E, S5B, and S5C).
LTCF4KO Mice Display Reduced Hepatic
Gluconeogenesis
To assess the effect of liver-specific TCF4 depletion on
whole-body glucose utilization, LTCF4KO and control mice
were fed with either NC or HF diet. We observed no significant
differences in body weight, gain of weight, and food intake
between LTCF4KO and control mice on HF diet during an
8 week period (Figures S6D–S6F). However, we observed
significantly reduced glucose levels in fasting LTCF4KO mice
when compared to control mice (p < 0.05) (Figure S6J). This
reduced glucose level was not caused by hyperinsulinemia
(Figures S6K andS6L). Indeed, glucose-stimulated insulin secre-
tion did not differ between LTCF4KO and control mice (Fig-
ure S6N) on HF diet.
Intraperitoneal GTT were performed on LTCF4KO and control
mice maintained on both diets. Although we observed a mild
phenotype in LTCF4KO mice fed with NC diet (Figure S7A),
upon challenge with HF diet, the mice exhibited a significantly
lower increase in glucose levels (p < 0.05) (Figure S7B). Following
injection of pyruvate, we also observed that glucose levels were
lower in LTCF4KO mice on NC diet (Figure 7E) and became
significantly less increased in LTCF4KO upon challenge with
HF diet (p < 0.05) (Figure 7F). Collectively, these results indicated
that LTCF4KO mice have a reduced hepatic gluconeogenesis
that becomes more pronounced when mice are challenged
with HF diet. To directly examine the effect of TCF4 deficiency
on hepatic glucose production in vitro, hepatocytes from control
and LTCF4KO mice on HF diet were isolated and assayed in
culture. TCF4 null hepatocytes secreted less glucose than
controls following either glucagon or IBMX (3-isobutyl-1-methyl-(D) GSEA showing a significant enrichment of genes bound by TCF4 among the
(E) qPCR was performed to determine enrichment of TCF4 and IgG control in th
(F) Luciferase units relative to the activity detected of the respective empty vecto
(G) Same constructs described above were cotransfected with control or DNTCF
activity of the respective empty vector.
Data are represented as mean ±SEM from three independent experiments. *p < 0
Cxanthine) stimulation, indicating an intrinsic impairment of
glucose production (Figure S7C). The induction of TCF4-depen-
dent G6pc and Aldh3a2 mRNA levels in response to glucagon
stimulation, as a surrogate of fasting, was significantly abrogated
in LTCF4KO hepatocytes (p < 0.05) (Figure S7D).
Effects of Liver-Specific Overexpression of TCF4 In Vivo
Opposite to LTCF4KO
Adult liver-specific Tcf7l2 knockout mice (LTCF4KO) showed
reduced blood glucose levels and hepatic glucose production.
To determine whether overexpression of TCF4 specifically in
the liver induces the opposite phenotype, we analyzed the meta-
bolic effects after transient hepatic overexpression of TCF4 by
using replication-deficient adenovirus administered by tail vein
injection into adult mice (Fechner et al., 1999). In mice injected
with TCF4 adenovirus (Ad-TCF4), 50% of the nuclei displayed
increased expression of TCF4 (Figure 7G, right, white arrow-
heads). Ad-TCF4-injected mice displayed a significant increase
in serum glucose under fasting conditions (Figure S7E) com-
pared to controls. This difference was not due to a reduction in
circulating insulin concentrations (Figures S7F and S7G).
Consistent with our observation after liver-specific deletion of
TCF4, overexpression of TCF4 specifically in the liver led to an
increased hepatic glucose production upon pyruvate injection
(Figure 7H).
qPCR analyses revealed an upregulation of the generic
Wnt target genes (Axin2 and Sp5) and liver-zonated genes
(Glul and Rnase4) (p < 0.05) (Figure S7I), implying that elevating
TCF4 indeed enhances the transcriptional Wnt response. This
induction also occurred for the metabolic genes that were direct
targets of TCF4 (Aldh3a2, St3gal5, Slc1a2, and G6pc) (p < 0.05)
(Figure 7I). Of note, metabolic genes that were not TCF4 targets
(Pck1 and Fbp1) were not upregulated after TCF4 overexpres-
sion (Figure 7I). Thus, in the adult liver, genetic overexpression
of TCF4 leads to the opposite effect of removal of TCF4 in terms
of glucose metabolism and of expression of the Wnt-responsive
metabolic genes.
DISCUSSION
Most studies on the involvement of TCF7L2 SNP variants in type
2 diabetes (T2D) focus on a role of TCF4 in pancreatic islets and
b cells (da Silva Xavier et al., 2009; Lyssenko et al., 2007; Shu
et al., 2008, 2009). In this study, we utilize mouse genetics to
show that removal of TCF4 from b cells does not affect their func-
tion. These observations are made in newborn Tcf7l2/ mice
and in adult b-cell-specific Tcf7l2mutants, challenged by fasting
or by high-fat diet. The previously reported changes in b cell
function possibly result indirectly from changes elsewhere in
the body. In this study, we have focused on the transcriptional
role of TCF4 in liver metabolism. We believe it highly likely thatgenes downregulated in Tcf7l2/ newborn livers.
e proximal promoters and enhancers of several TCF4 target genes.
r.
4 (dominant-negative TCF4) plasmid. Values were normalized to the luciferase
.05, **p < 0.01, and ***p < 0.001. See also Figure S5 and Tables S2, S3, and S4.
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Figure 7. Modulation of TCF4 Levels in the Liver Affects Hepatic Glucose Production
(A) Blood glucose levels of control and LTCF4KO mice during the course of a 24 hr fast.
(B) Heatmap showing genes upregulated more than 2-fold with p < 0.05 in 24-hr-fasted versus fed comparison in control and the comparison of the corre-
sponding upregulation in LTCF4KO adult livers. Red, upregulated; green, downregulated; black, no change; gray, missing data.
(C) GSEA showing significant enrichment of genes bound by TCF4 among the genes downregulated in LTCF4KO adult livers in 24-hr-fasted state.
(D) qRT-PCR tomeasure relative mRNA levels of metabolic genes involved in the response to fasting and gluconeogenesis. All qRT-PCR results were normalized
to housekeeping mRNA levels and are expressed relative to control fed samples.
(legend continued on next page)
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a Wnt/TCF4 axis may similarly control transcriptional responses
to metabolic challenge in, for instance, muscle or white adipose
tissue.
The Wnt pathway controls postnatal hepatic growth (Apte
et al., 2007) and postnatal liver zonation (Spear et al., 2006).
We now show that TCF4 controls physiological energy-related
functions of the neonatal and adult liver and that Wnt target
genes are activated in response to metabolic demand in
a TCF4-dependent manner. We thus identify a liver-specific
TCF4-controlled gene program. Importantly, this liver-specific
set of TCF4 target genes includes some generic Wnt target
genes, but it otherwise mainly covers pathways related to
metabolism, such as gluconeogenesis, transport of fatty acids,
and synthesis of ketone bodies.
The current observations imply the following scenario. TCF4 is
dispensable during embryonic development, likely due to redun-
dancy with other TCF/LEF family members (Gregorieff et al.,
2004). Moreover, it is not required for the baseline expression
of its metabolic target genes throughout life, yet its function in
metabolic control becomes evident under situations of meta-
bolic demand. Its first essential role is revealed directly after
birth. The immediate postnatal surge in the production of energy
carriers by the liver (when placenta function is acutely disrupted)
does not occur in TCF4mutant mice, leading to their rapid death.
Indeed, a large set of keymetabolic liver genes are dependent on
TCF4 for their induced expression after birth. We find that many
of these genes are physically occupied by TCF4. Several generic
Wnt target genes (Axin2 and Sp5), as well as Wnt target liver-zo-
nated genes (Glul and Rnase4), are coregulated with the set of
metabolic TCF4 target genes. Several Wnt ligands are induced
perinatally. This metabolic function of TCF4 is conserved into
adulthood. Similar to our observations in Tcf7l2 mutant
newborns, fasting adult mice carrying a liver-specific Tcf7l2
null mutation fail to induce generic Wnt target genes and meta-
bolic genes involved in hepatic glucose production. As in the
neonate, fasting induces several Wnt ligands. Taken together,
Wnt signals activate the ‘‘surges’’ in liver metabolism that occur
in the immediate postnatal period and upon metabolic demand
in the adult.
In accordance with this, a recent study has used a transgenic
mouse approach to demonstrate that the diabetes-associated
SNP variants of the TCF7L2 locus give rise to gain-of-expression
alleles (Savic et al., 2011). Our adenovirus experiment demon-
strates that increased liver-specific expression of TCF4 leads
to increased glucose production. Indeed, an increase in fasting
hepatic glucose production has been observed in human
carriers of TCF7L2 risk alleles (Lyssenko et al., 2007; Pilgaard
et al., 2009). These observationsmay provide amolecular frame-(E and F) PTT in LTCF4KO and control mice feed during 8 weeks with either cho
(G) Liver sections stained with anti-TCF4 (brown) and hematoxylin (blue) in contro
adenovirus injection. Magnification: 43 (left) and 103 (right). Black arrowheads in
indicate hepatocytes overexpressing TCF4.
(H) PTT in control and mice overexpressing human TCF4.
(I) qRT-PCR to measure relative mRNA levels of metabolic genes involved in the r
to housekeeping mRNA levels and were given relative to Ad-Control mice.
Data are represented asmean ±SEM; n = 10–20 per genotype (n = 6 per genotype
and S6.
Cwork from which to understand the role of TCF7L2/TCF4 in the
development of diabetes.
EXPERIMENTAL PROCEDURES
Animals
All different mouse models generated and analyzed are described extensively
in the Supplemental Information.
Glucose and Insulin Tolerance, Insulin Secretion, Pyruvate
Challenge, and Long-Term Fasting Tests
For glucose (GTT) and pyruvate (PTT) tolerance tests, mice were deprived of
food for 16 hr and were injected i.p. with either glucose or pyruvate (2 g/kg
body weight). Glucose from tail vein blood was then measured at time 0, 15,
30, 60, and 120 min. For insulin tolerance test (ITT), mice were deprived of
food for 4 hr and were injected i.p. with insulin (0.75 units/body weight).
Glucose from tail vein was then measured at time 0, 15, 30, 60, and 90 min.
For glucose-stimulated insulin secretion test, mice were deprived of food for
16 hr and injected i.p. with glucose (3 g/kg body weight), and blood was
collected from the tail vein at 0 and 15 min after injection. For long-term fasting
experiments, blood was sampled from the tail vein of mice, which were al-
lowed to feed ad libitum (time 0) or fasted for 3, 6, 9, 12, or 24 hr. Blood glucose
concentrations were always measured with Glucometer FreeStyle (Abbott).
Serum Biochemical Measurements
Serum blood samples were collected with Microvette CB300 capillary (Sar-
stedt). Plasma insulin (Mercodia), free fatty acid (BioVision), triglycerides
(BioAssay systems), and ketone body (BioVision) measurements were per-
formed by ELISA.
Glycogen and Triglyceride Assays
Tissues samples from 5 hhp Tcf7l2+/+, Tcf7l2+/, and Tcf7l2/ newborn livers
were homogenized in 6% PCA (Perchloric Acid) (200 ml/50 mg tissue). The
supernatant was collected, one volume of H2O was added, and the solution
was adjusted to pH 6.5 with 10 N KOH. A fraction of each sample was incu-
bated with five volumes of amyloglucosidase (A7420, Sigma Aldrich) (1 mg/
ml in 0.2 M [pH 4.8] acetate buffer) at 40C for 2 hr. Glucose concentrations
were then determined by using the Amplex Red Glucose/Glucose Oxidase
Assay Kit (Invitrogen). Samples incubated in the absence of amyloglucosidase
were used as a baseline controls.
In case of measuring triglyceride levels, liver samples were homogenized in
chloroform: methanol (2:1) (500 ml/50 mg tissue). 100 ml of 0.9% NaCl were
added, and samples were vortexed for 2 min and centrifuged at 2,000 rpm
for 5 min. Organic phase was recovered and lyophilized. Samples were resus-
pended in PBS-1%Triton before measurement.
Pancreatic Islet Isolation, Insulin Secretion, and Insulin Content
Pancreatic islets from bTCF4KO, LTCF4KO, and respective control mice were
isolated as previously described (Pa´rrizas et al., 2001). For secretion studies,
pancreatic islets were allowed to recover for 1 day in culture in RPMI contain-
ing 11 mM glucose supplemented with 10% fetal calf serum and penicillin-
streptomycin at 37C and 5% CO2. Equal numbers of size-matched islets
were subjected to stimulation of insulin secretion at 1.6 and 16.7 mM glucose.
After 1 hr of incubation in each condition, medium was collected, and insulin
levels were assessed by ELISA. To measure insulin content in isolated islets,w (D) or high-fat (E) diet.
l (Ad-Control) and TCF4-overexpressing (Ad-TCF4) mice sacrificed 4 days after
dicate endogenous TCF4 levels in the hepatocytes, whereas white arrowheads
esponse to fasting and gluconeogenesis. All qRT-PCR results were normalized
in [H] and [I]). *p < 0.05 and **p < 0.01. See also Figures S6 and S7 and Tables S5
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pancreatic islets were sonicated in acid ethanol on ice for 15 s three times. All
extracts were stored at 20C for subsequent ELISA.
RNA Extraction, Microarray Analysis, and RT-PCR
Total RNA was obtained from embryonic, newborn, and adult liver, newborn
pancreas, and adult isolated pancreatic islets and hepatocytes. RNA extrac-
tion and reverse transcription (RT) were performed as described (Pa´rrizas
et al., 2001). For expression profile comparison between 5 hpp Tcf7l2/
and Tcf7l2+/+ livers and between fed and 24-hr-fasted control and LTCF4KO
livers, 1 mg of total RNA from four liver samples for each genotype, together
with universal mouse reference RNA (Stratagene), were labeled by using Quick
Amp Labeling Kit (Agilent Technologies) with Cy5 and Cy3, respectively.
Samples were hybridized on 4x44K Whole Mouse Genome Microarrays
(Agilent, G4122F) according to manufacturer’s instruction. Microarray signal
and background information were retrieved by using Feature Extraction
(V.9.5.3., Agilent Technologies). For each pair of experiments, fluorescent
signals in either channel with greater than 2-fold above the background
were considered. Genes that were present in less than three out of eight
arrays (four pairs of control and mutant samples for each comparison) were
excluded from further analysis. Corresponding fold changes greater than
2-fold variations between average of the control and mutant samples with
p < 0.05 (Student’s t test) were considered as significant. The data were
mean centered across samples for comparison in Figure 5A. The comparison
between 5 hpp Tcf7l2/ and Tcf7l2+/+ livers resulted in 960 significant unique
genes differentially expressed in Tcf7l2/ postnatal liver samples (Table S1).
The comparison between 24-hr-fasted versus fed adult control and LTCF4KO
livers resulted in 623 unique genes significantly less upregulated in LTCF4KO
samples (Table S5).
Selected candidate genes were further validated by qRT-PCR. qRT-PCR
was performed on iCycler iQ Real-Time PCR Detection Systems (Bio-Rad)
by using iQSYBRGreen supermix (Bio-Rad). All qRT-PCR resultswere normal-
ized to Tbp mRNA levels. Similar results were obtained when using Hprt and
b-actin to normalize. In Figures 3, 4, and 5, the WT embryonic samples were
used as a reference and were compared to the mutant embryonic, WT
newborn, and mutant newborn samples. In Figure 7, the fed control samples
were used as a reference andwere compared to the fedmutant, fasted control,
and fasted mutant samples. Primer sequences are described in Table S7.
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